Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.
Lead Product(s): Crofelemer
Therapeutic Area: Genetic Disease Product Name: Mytesi
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Jaguar Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
The company's initial focus is on clinical development and future registration in Europe of Mytesi (crofelemer) for two debilitating rare disease target indications: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) with intestinal failure.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: $58.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 09, 2023